Skip to main content
main-content

30.01.2017 | Onkologie | Online-Artikel

Inhibition of HER2 driver mutations can confer benefits

share
TEILEN

Figure: Responses to pyrotinib in 11 patients with advanced, HER2-positive NSCLC